CytoDyn Inc. (CYDY)
| Market Cap | 317.63M |
| Revenue (ttm) | n/a |
| Net Income | -40.35M |
| EPS | -0.03 |
| Shares Out | 1.27B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,417,337 |
| Average Volume | 1,855,055 |
| Open | 0.2624 |
| Previous Close | 0.2511 |
| Day's Range | 0.2451 - 0.2699 |
| 52-Week Range | 0.1761 - 0.4945 |
| Beta | 1.12 |
| RSI | 34.61 |
| Earnings Date | Jan 9, 2026 |
About CytoDyn
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. Cy... [Read more]
Financial Performance
Financial StatementsNews
CytoDyn Secures Funding To Launch Expanded Access Program For Leronlimab In Breast Cancer
(RTTNews) - CytoDyn Inc. (CYDY) has received dedicated funding from a compassionate benefactor to initiate an Expanded Access Program (EAP) for patients with triple-negative breast cancer, marking a k...
CytoDyn (CYDY) Secures Funding for Breast Cancer Program
CytoDyn (CYDY) Secures Funding for Breast Cancer Program
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
CytoDyn (CYDY) Anticipates Significant Progress in 2026
CytoDyn (CYDY) Anticipates Significant Progress in 2026
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your s...
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells
CytoDyn Announces Resolution of Class Action Lawsuit
VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Company to deliver a poster presentation on clinical data demonstrating sustained remission following immune checkpoint inhibitor therapy with or after leronlimab treatment in patients with metastatic...
CytoDyn (CYDY) Secures $30 Million Funding Commitment from Yorkville
CytoDyn (CYDY) Secures $30 Million Funding Commitment from Yorkville
CytoDyn (CYDY) Secures $30M Funding for Cancer Drug Development
CytoDyn (CYDY) Secures $30M Funding for Cancer Drug Development
CytoDyn secures $30M equity funding commitment
CytoDyn secures $30M funding to advance leronlimab for cancer treatment. Learn how this impacts biotech investing.
CytoDyn Secures $30 Million Commitment from Yorkville Advisors
VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of CytoDyn Inc. (OTCMKTS: CYDY) breached their fiduciary duties to sha...
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-s...
September 2025 Letter to Shareholders
VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progr...
CytoDyn (CYDY) Highlights Promising Cancer Research at AACR Conference
CytoDyn (CYDY) Highlights Promising Cancer Research at AACR Conference
CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
Company to deliver oral and poster presentations for data on leronlimab's action on PD-L1 expression and patient survival in triple-negative breast cancer
CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mo...
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humaniz...
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanize...
CytoDyn files $100M mixed securities shelf
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health
A Penny Stock To Watch In Challenging Cancer Space
We have a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 Months. The stock’s current price is around $0.32. CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leron...
CytoDyn Releases ESMO Breast Cancer Meeting Poster
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...